A rapid and simple assay to determine pegylated erythropoietin in human serum

Journal of Applied Physiology

Volumn 108, Issue 4, 2010, Pages 800-803

  Van Maerken, Tom ^a   Dhondt, Annemieke ^a   Delanghe, Joris R ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Continuous erythropoietin receptor activator; Detection; Doping; Endurance sports

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; MACROGOL DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BIOASSAY; BLOOD; CHRONIC KIDNEY FAILURE; DOPING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BIOLOGICAL ASSAY; DOPING IN SPORTS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 77950567135     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01102.2009     Document Type: Article

References (15)

1. Ayotte C, Gmeiner G, Lasne F, Pascual JA, Reichet C, Saugy M. WADA Technical Document, TD2009EPO version 2.0. Harmonization of the method for the identification of recombinant erythropoietins (i.e., epoetins) and analogues (i.e., darbepoetin and pegseipoetin) [Online]. World Anti-Doping Agency, http://www.wada-ama.org/rtecontent/document/ TD-EPO-2009.pdf [Jan. 17, 2010].
2. Davidson DF, Watson DJ. Macroenzyme detection by polyethylene glycol precipitation. Ann Clin Biochem 40: 514-520, 2003.
3. Delanghe JR, Bollen M, Beullens M. Testing for recombinant erythropoietin. Am J Hematol 83: 237-241, 2008.
4. 4. Franke WW, Heid H. Pitfalls, errors and risks of false-positive results in urinary EPO drug tests. Clin Chim Acta 373: 189-190, 2006. (Pubitemid 44292189)
5. Lamon S, Giraud S, Egli L, Smolander J, Jarsch M, Stubenrauch KG, Hellwig A, Saugy M, Robinson N. A high-throughput test to detect CERA doping in blood. J Pharm Biomed Anal 50: 954-958, 2009.
6. Lasne F, Martin L, Martin JA, de Ceaurriz J. Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control. Haematologica 94: 888-890, 2009.
7. 7. Levitt MD, Ellis C. A rapid and simple assay to determine if macroamylase is the cause of hyperamylasemia. Gastroenterology 83: 378-382, 1982. (Pubitemid 12078221)
8. Lundby C, Achman-Andersen NJ, Thomsen JJ, Norgaard AM, Robach P. Testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing. J Appl Physiol 105: 417-419, 2008.
9. Panchapakesan U, Sumual S, Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (continuous erythropoietin receptor activator). Int J Nanomedicine 2: 33-38, 2007.
10. 10. Parveen S, Sahoo SK. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 45: 965-988, 2006. (Pubitemid 44436001)
11. Reichet C, Abzieher F, Geisendorfer T. SARCOS YL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood. Drug Test Analysis. 1: 494-594, 2009.
12. Reichet C, Kulovics R, Jordan V, Watzinger M, Geisendorfer T. SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. Drug Test Analysis 1: 43-50, 2009.
13. Simpson RJ. Concentrating solutions of proteins. In: Purifying Proteins For Proteomics: A Laboratory Manual, edited by Simpson RJ. New York: Cold Spring Harbor Laboratory, 2004.
14. Vieira JG, Tachibana TT, Obara LH, Maciel RM. Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin Chem 44: 1758-1759, 1998.
15. World Anti-Doping Agency. International standard for laboratories - version 6.0 [Online], World Anti-Doping Agency, http://www.wada-ama.org/ rtecontent/document/International-Standard-for-Laboratories-v6-0- January-2009.pdf [Jan. 17, 2010].